At Sunovion, we are committed to researching and developing treatments for individuals with unmet medical needs. In collaboration with the Sumitomo Dainippon Pharma's Group and our teams of scientists in Fort Lee, New Jersey, Marlborough, Massachusetts and Osaka, Japan, our goal is to provide patients with new treatment options that are more effective than existing therapies in improving their conditions and with greater speed.
We focus our discovery research on psychiatric indications such as schizophrenia, depression, cognitive function and bipolar disease. We are taking a fresh approach to drug discovery by partnering with external biotech, contract research and academic organizations to find potential treatments in areas of high unmet need. By engaging external innovation partners, we will be able to more effectively turn our ideas into new drugs.